1,351
Views
1
CrossRef citations to date
0
Altmetric
Articles

Prostate biopsy quality and patient experience with the novel Forsvall biopsy needle – a randomized controlled non-inferiority trial

ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon & ORCID Icon show all
Pages 235-241 | Received 12 Feb 2021, Accepted 19 Apr 2021, Published online: 17 May 2021

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • Liss MA, Ehdaie B, Loeb S, et al. An update of the american urological association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329–334.
  • Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876–892.
  • Liss MA, Johnson JR, Porter SB, et al. Clinical and microbiological determinants of infection after transrectal prostate biopsy. Clin Infect Dis. 2015;60(7):979–987.
  • Johansen TEB, Zahl PH, Baco E, et al. Antibiotic resistance, hospitalizations, and mortality related to prostate biopsy: first report from the Norwegian Patient Registry. World J Urol. 2020;38(1):17–26.
  • Forsvall A, Jönsson H, Wagenius M, et al. Rate and characteristics of infection after transrectal prostate biopsy – a retrospective observational study. Scand J Urol. 2021. doi:10.1080/21681805.2021.1933169.
  • Liss MA, Taylor SA, Batura D, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol. 2014;192(6):1673–1678.
  • Forsvall A, Fisher J, Cardoso JFP, et al. Evaluation of the Forsvall biopsy needle in an ex vivo model of transrectal prostate biopsy - A novel needle design with the objective to reduce the risk of post-biopsy infection. Scand J Urol. 2021;55(3):227–234.
  • Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011;152(10):2399–2404.
  • Fajardo DA, Epstein JI. Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. BJU Int. 2010;105(2):172–175.
  • Ergün M, İslamoğlu E, Yalçınkaya S, et al. Does length of prostate biopsy cores have an impact on diagnosis of prostate cancer? Turk J Urol. 2016;42(3):130–133.
  • Fiset PO, Aprikian A, Brimo F. Length of prostate biopsy cores: does it impact cancer detection? Can J Urol. 2013;20(4):6848–6853.
  • Yılmaz H, Yavuz U, Üstüner M, et al. Longer biopsy cores do not increase prostate cancer detection rate: A large-scale cohort study refuting cut-off values indicated in the literature. Turkish Journal of Urology. 2017;43(3):297–302.
  • Reis LO, Sanches BC, de Mendonça GB, et al. Gleason underestimation is predicted by prostate biopsy core length. World J Urol. 2015;33(6):821–826.